Industry Overview

North America CDMO market was valued at $100.6 billion in 2025 and is projected to reach $183.2 billion by 2035, growing at a CAGR of 6.2% during the forecast period (2026–2035). The North American healthcare contract development and manufacturing organization market is expanding as pharmaceutical companies increasingly rely on external partners to manage complex development and production requirements. Strong demand for biologics, specialty drugs, and sterile formulations continues to support outsourcing activity. The region benefits from advanced manufacturing infrastructure and a mature regulatory framework that enables efficient scale-up and commercialization. Ongoing investment in process automation and quality systems is improving operational efficiency. Growth is further supported by an active biotechnology sector seeking flexible development support. Collectively, these factors are sustaining steady market advancement through the forecast period.

Market Dynamics

Acceleration of Advanced Therapy Manufacturing

North American CDMOs are seeing rising demand for cell and gene therapies, biologics, and other high-complexity products. This shift is driven by robust clinical pipelines and increased regulatory approvals for advanced treatments. Leading service providers are expanding specialized facilities and investing in high-containment and single-use technologies. Recent developments include capacity additions focused on viral vectors and sterile injectables. These capabilities are positioning the region as a preferred hub for advanced therapy outsourcing.

Integration of End-to-End Service Models

Pharmaceutical and biotechnology companies are increasingly selecting CDMOs that offer integrated development and manufacturing services under a single contract. This approach improves coordination across development stages and reduces time-to-market. Key players are strengthening analytical, regulatory, and commercial-scale manufacturing capabilities. Recent trends show increased long-term agreements and strategic collaborations. This model is enhancing operational continuity and long-term client engagement.

Market Segmentation

• Based on the services, the market is segmented into contract development and contract manufacturing.

Contract Manufacturing Segment to Lead the Market with the Largest Share

Contract manufacturing represents the leading service segment in the North American CDMO market, driven by strong demand for large-scale, commercial production of pharmaceuticals and biologics. Pharmaceutical companies increasingly outsource manufacturing to manage capacity constraints, control capital expenditure, and ensure compliance with stringent quality standards. Major CDMOs with established facilities and proven regulatory track records dominate this segment, particularly in sterile injectables and biologics. Recent trends include plant expansions, adoption of continuous manufacturing, and increased use of single-use systems. These developments support faster scale-up and reliable supply for both branded and generic products.

Contract Development: A Key Segment in Market Growth

Contract development services are expanding steadily as biotechnology and emerging pharmaceutical firms seek external expertise during early and mid-stage drug development. Growth is supported by rising demand for formulation development, analytical testing, and process optimization. CDMOs offering integrated development capabilities are gaining preference, especially for complex molecules and biologics. Recent activity highlights greater use of digital tools, quality-by-design methodologies, and regulatory support services. This segment plays a critical role in reducing technical risk before commercialization.

Regional Outlook

The North America CDMO market is further divided by countries, including the US and Canada.

US Dominates the Market with Major Share

The US is the leading country in the North American CDMO market, driven by its dominant pharmaceutical and biotechnology industries and advanced manufacturing infrastructure. The country hosts a high concentration of top-tier CDMOs offering both development and large-scale manufacturing services for small molecules, biologics, and complex therapies. Growth is fueled by strong R&D pipelines, increasing demand for biologics and specialty drugs, and strategic outsourcing by both large pharmaceutical companies and emerging biotech firms. Recent trends include facility expansions, investment in single-use and continuous manufacturing technologies, and partnerships to support advanced therapy production. A robust regulatory framework and skilled workforce further reinforce the US as the primary hub for CDMO activities in the region.

Market Players Outlook

The major companies operating in the North America CDMO market include Thermo Fisher Scientific Inc., Lonza Group AG, WuXi AppTec Co., Ltd., WuXi Biologics Co., Ltd., and Eurofins Scientific SE, among others. Market players are leveraging partnerships, collaborations, mergers, and acquisition strategies for business expansion and innovative product development to maintain their market positioning.

Recent Development

• In April 2025, PCI Pharma Services acquired an entire equity stake in Ajinomoto Althea, Inc. The acquisition provides PCI with its first-ever North American manufacturing location for prefilled syringes and cartridges, including isolator technology for these formats, as well as high-potency manufacturing suitable for antibody-drug conjugates (ADCs).

The Report Covers

• Market value data analysis of 2025 and forecast to 2035.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the North America CDMO market. Based on the availability of data, information related to new products and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.